Cargando…

Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study

BACKGROUND: The objectives of this study were to identify risk factors for severe coronavirus disease 2019 (COVID-19) and to lay the basis for risk stratification based on demographic data and health records. METHODS AND FINDINGS: The design was a matched case-control study. Severe COVID-19 was defi...

Descripción completa

Detalles Bibliográficos
Autores principales: McKeigue, Paul M., Weir, Amanda, Bishop, Jen, McGurnaghan, Stuart J., Kennedy, Sharon, McAllister, David, Robertson, Chris, Wood, Rachael, Lone, Nazir, Murray, Janet, Caparrotta, Thomas M., Smith-Palmer, Alison, Goldberg, David, McMenamin, Jim, Ramsay, Colin, Hutchinson, Sharon, Colhoun, Helen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575101/
https://www.ncbi.nlm.nih.gov/pubmed/33079969
http://dx.doi.org/10.1371/journal.pmed.1003374
_version_ 1783597750349201408
author McKeigue, Paul M.
Weir, Amanda
Bishop, Jen
McGurnaghan, Stuart J.
Kennedy, Sharon
McAllister, David
Robertson, Chris
Wood, Rachael
Lone, Nazir
Murray, Janet
Caparrotta, Thomas M.
Smith-Palmer, Alison
Goldberg, David
McMenamin, Jim
Ramsay, Colin
Hutchinson, Sharon
Colhoun, Helen M.
author_facet McKeigue, Paul M.
Weir, Amanda
Bishop, Jen
McGurnaghan, Stuart J.
Kennedy, Sharon
McAllister, David
Robertson, Chris
Wood, Rachael
Lone, Nazir
Murray, Janet
Caparrotta, Thomas M.
Smith-Palmer, Alison
Goldberg, David
McMenamin, Jim
Ramsay, Colin
Hutchinson, Sharon
Colhoun, Helen M.
author_sort McKeigue, Paul M.
collection PubMed
description BACKGROUND: The objectives of this study were to identify risk factors for severe coronavirus disease 2019 (COVID-19) and to lay the basis for risk stratification based on demographic data and health records. METHODS AND FINDINGS: The design was a matched case-control study. Severe COVID-19 was defined as either a positive nucleic acid test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the national database followed by entry to a critical care unit or death within 28 days or a death certificate with COVID-19 as underlying cause. Up to 10 controls per case matched for sex, age, and primary care practice were selected from the national population register. For this analysis—based on ascertainment of positive test results up to 6 June 2020, entry to critical care up to 14 June 2020, and deaths registered up to 14 June 2020—there were 36,948 controls and 4,272 cases, of which 1,894 (44%) were care home residents. All diagnostic codes from the past 5 years of hospitalisation records and all drug codes from prescriptions dispensed during the past 240 days were extracted. Rate ratios for severe COVID-19 were estimated by conditional logistic regression. In a logistic regression using the age-sex distribution of the national population, the odds ratios for severe disease were 2.87 for a 10-year increase in age and 1.63 for male sex. In the case-control analysis, the strongest risk factor was residence in a care home, with rate ratio 21.4 (95% CI 19.1–23.9, p = 8 × 10(−644)). Univariate rate ratios for conditions listed by public health agencies as conferring high risk were 2.75 (95% CI 1.96–3.88, p = 6 × 10(−9)) for type 1 diabetes, 1.60 (95% CI 1.48–1.74, p = 8 × 10(−30)) for type 2 diabetes, 1.49 (95% CI 1.37–1.61, p = 3 × 10(−21)) for ischemic heart disease, 2.23 (95% CI 2.08–2.39, p = 4 × 10(−109)) for other heart disease, 1.96 (95% CI 1.83–2.10, p = 2 × 10(−78)) for chronic lower respiratory tract disease, 4.06 (95% CI 3.15–5.23, p = 3 × 10(−27)) for chronic kidney disease, 5.4 (95% CI 4.9–5.8, p = 1 × 10(−354)) for neurological disease, 3.61 (95% CI 2.60–5.00, p = 2 × 10(−14)) for chronic liver disease, and 2.66 (95% CI 1.86–3.79, p = 7 × 10(−8)) for immune deficiency or suppression. Seventy-eight percent of cases and 52% of controls had at least one listed condition (51% of cases and 11% of controls under age 40). Severe disease was associated with encashment of at least one prescription in the past 9 months and with at least one hospital admission in the past 5 years (rate ratios 3.10 [95% CI 2.59–3.71] and 2.75 [95% CI 2.53–2.99], respectively) even after adjusting for the listed conditions. In those without listed conditions, significant associations with severe disease were seen across many hospital diagnoses and drug categories. Age and sex provided 2.58 bits of information for discrimination. A model based on demographic variables, listed conditions, hospital diagnoses, and prescriptions provided an additional 1.07 bits (C-statistic 0.804). A limitation of this study is that records from primary care were not available. CONCLUSIONS: We have shown that, along with older age and male sex, severe COVID-19 is strongly associated with past medical history across all age groups. Many comorbidities beyond the risk conditions designated by public health agencies contribute to this. A risk classifier that uses all the information available in health records, rather than only a limited set of conditions, will more accurately discriminate between low-risk and high-risk individuals who may require shielding until the epidemic is over.
format Online
Article
Text
id pubmed-7575101
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-75751012020-10-26 Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study McKeigue, Paul M. Weir, Amanda Bishop, Jen McGurnaghan, Stuart J. Kennedy, Sharon McAllister, David Robertson, Chris Wood, Rachael Lone, Nazir Murray, Janet Caparrotta, Thomas M. Smith-Palmer, Alison Goldberg, David McMenamin, Jim Ramsay, Colin Hutchinson, Sharon Colhoun, Helen M. PLoS Med Research Article BACKGROUND: The objectives of this study were to identify risk factors for severe coronavirus disease 2019 (COVID-19) and to lay the basis for risk stratification based on demographic data and health records. METHODS AND FINDINGS: The design was a matched case-control study. Severe COVID-19 was defined as either a positive nucleic acid test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the national database followed by entry to a critical care unit or death within 28 days or a death certificate with COVID-19 as underlying cause. Up to 10 controls per case matched for sex, age, and primary care practice were selected from the national population register. For this analysis—based on ascertainment of positive test results up to 6 June 2020, entry to critical care up to 14 June 2020, and deaths registered up to 14 June 2020—there were 36,948 controls and 4,272 cases, of which 1,894 (44%) were care home residents. All diagnostic codes from the past 5 years of hospitalisation records and all drug codes from prescriptions dispensed during the past 240 days were extracted. Rate ratios for severe COVID-19 were estimated by conditional logistic regression. In a logistic regression using the age-sex distribution of the national population, the odds ratios for severe disease were 2.87 for a 10-year increase in age and 1.63 for male sex. In the case-control analysis, the strongest risk factor was residence in a care home, with rate ratio 21.4 (95% CI 19.1–23.9, p = 8 × 10(−644)). Univariate rate ratios for conditions listed by public health agencies as conferring high risk were 2.75 (95% CI 1.96–3.88, p = 6 × 10(−9)) for type 1 diabetes, 1.60 (95% CI 1.48–1.74, p = 8 × 10(−30)) for type 2 diabetes, 1.49 (95% CI 1.37–1.61, p = 3 × 10(−21)) for ischemic heart disease, 2.23 (95% CI 2.08–2.39, p = 4 × 10(−109)) for other heart disease, 1.96 (95% CI 1.83–2.10, p = 2 × 10(−78)) for chronic lower respiratory tract disease, 4.06 (95% CI 3.15–5.23, p = 3 × 10(−27)) for chronic kidney disease, 5.4 (95% CI 4.9–5.8, p = 1 × 10(−354)) for neurological disease, 3.61 (95% CI 2.60–5.00, p = 2 × 10(−14)) for chronic liver disease, and 2.66 (95% CI 1.86–3.79, p = 7 × 10(−8)) for immune deficiency or suppression. Seventy-eight percent of cases and 52% of controls had at least one listed condition (51% of cases and 11% of controls under age 40). Severe disease was associated with encashment of at least one prescription in the past 9 months and with at least one hospital admission in the past 5 years (rate ratios 3.10 [95% CI 2.59–3.71] and 2.75 [95% CI 2.53–2.99], respectively) even after adjusting for the listed conditions. In those without listed conditions, significant associations with severe disease were seen across many hospital diagnoses and drug categories. Age and sex provided 2.58 bits of information for discrimination. A model based on demographic variables, listed conditions, hospital diagnoses, and prescriptions provided an additional 1.07 bits (C-statistic 0.804). A limitation of this study is that records from primary care were not available. CONCLUSIONS: We have shown that, along with older age and male sex, severe COVID-19 is strongly associated with past medical history across all age groups. Many comorbidities beyond the risk conditions designated by public health agencies contribute to this. A risk classifier that uses all the information available in health records, rather than only a limited set of conditions, will more accurately discriminate between low-risk and high-risk individuals who may require shielding until the epidemic is over. Public Library of Science 2020-10-20 /pmc/articles/PMC7575101/ /pubmed/33079969 http://dx.doi.org/10.1371/journal.pmed.1003374 Text en © 2020 McKeigue et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
McKeigue, Paul M.
Weir, Amanda
Bishop, Jen
McGurnaghan, Stuart J.
Kennedy, Sharon
McAllister, David
Robertson, Chris
Wood, Rachael
Lone, Nazir
Murray, Janet
Caparrotta, Thomas M.
Smith-Palmer, Alison
Goldberg, David
McMenamin, Jim
Ramsay, Colin
Hutchinson, Sharon
Colhoun, Helen M.
Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study
title Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study
title_full Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study
title_fullStr Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study
title_full_unstemmed Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study
title_short Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study
title_sort rapid epidemiological analysis of comorbidities and treatments as risk factors for covid-19 in scotland (react-scot): a population-based case-control study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575101/
https://www.ncbi.nlm.nih.gov/pubmed/33079969
http://dx.doi.org/10.1371/journal.pmed.1003374
work_keys_str_mv AT mckeiguepaulm rapidepidemiologicalanalysisofcomorbiditiesandtreatmentsasriskfactorsforcovid19inscotlandreactscotapopulationbasedcasecontrolstudy
AT weiramanda rapidepidemiologicalanalysisofcomorbiditiesandtreatmentsasriskfactorsforcovid19inscotlandreactscotapopulationbasedcasecontrolstudy
AT bishopjen rapidepidemiologicalanalysisofcomorbiditiesandtreatmentsasriskfactorsforcovid19inscotlandreactscotapopulationbasedcasecontrolstudy
AT mcgurnaghanstuartj rapidepidemiologicalanalysisofcomorbiditiesandtreatmentsasriskfactorsforcovid19inscotlandreactscotapopulationbasedcasecontrolstudy
AT kennedysharon rapidepidemiologicalanalysisofcomorbiditiesandtreatmentsasriskfactorsforcovid19inscotlandreactscotapopulationbasedcasecontrolstudy
AT mcallisterdavid rapidepidemiologicalanalysisofcomorbiditiesandtreatmentsasriskfactorsforcovid19inscotlandreactscotapopulationbasedcasecontrolstudy
AT robertsonchris rapidepidemiologicalanalysisofcomorbiditiesandtreatmentsasriskfactorsforcovid19inscotlandreactscotapopulationbasedcasecontrolstudy
AT woodrachael rapidepidemiologicalanalysisofcomorbiditiesandtreatmentsasriskfactorsforcovid19inscotlandreactscotapopulationbasedcasecontrolstudy
AT lonenazir rapidepidemiologicalanalysisofcomorbiditiesandtreatmentsasriskfactorsforcovid19inscotlandreactscotapopulationbasedcasecontrolstudy
AT murrayjanet rapidepidemiologicalanalysisofcomorbiditiesandtreatmentsasriskfactorsforcovid19inscotlandreactscotapopulationbasedcasecontrolstudy
AT caparrottathomasm rapidepidemiologicalanalysisofcomorbiditiesandtreatmentsasriskfactorsforcovid19inscotlandreactscotapopulationbasedcasecontrolstudy
AT smithpalmeralison rapidepidemiologicalanalysisofcomorbiditiesandtreatmentsasriskfactorsforcovid19inscotlandreactscotapopulationbasedcasecontrolstudy
AT goldbergdavid rapidepidemiologicalanalysisofcomorbiditiesandtreatmentsasriskfactorsforcovid19inscotlandreactscotapopulationbasedcasecontrolstudy
AT mcmenaminjim rapidepidemiologicalanalysisofcomorbiditiesandtreatmentsasriskfactorsforcovid19inscotlandreactscotapopulationbasedcasecontrolstudy
AT ramsaycolin rapidepidemiologicalanalysisofcomorbiditiesandtreatmentsasriskfactorsforcovid19inscotlandreactscotapopulationbasedcasecontrolstudy
AT hutchinsonsharon rapidepidemiologicalanalysisofcomorbiditiesandtreatmentsasriskfactorsforcovid19inscotlandreactscotapopulationbasedcasecontrolstudy
AT colhounhelenm rapidepidemiologicalanalysisofcomorbiditiesandtreatmentsasriskfactorsforcovid19inscotlandreactscotapopulationbasedcasecontrolstudy
AT rapidepidemiologicalanalysisofcomorbiditiesandtreatmentsasriskfactorsforcovid19inscotlandreactscotapopulationbasedcasecontrolstudy